Assessment of the Reactogenicity of ADACEL (TdcP Vaccine) in Children and Adolescents 7 to 19 Years of Age

Trial Profile

Assessment of the Reactogenicity of ADACEL (TdcP Vaccine) in Children and Adolescents 7 to 19 Years of Age

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Jan 2014

At a glance

  • Drugs DTaP vaccine (Primary)
  • Indications Diphtheria; Pertussis; Tetanus
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 24 Sep 2008 Actual end date added as 1 Sep 2005 as reported by ClinicalTrials.gov.
    • 24 Sep 2008 Actual initiation date added as 1 Sep 2004 as reported by ClinicalTrials.gov.
    • 24 Sep 2008 Actual patient number is changed from 13238 to 7159 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top